{"id":"NCT02339974","sponsor":"Henry Ford Health System","briefTitle":"Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)","officialTitle":"Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2024-12","completion":"2025-06","firstPosted":"2015-01-16","resultsPosted":"2025-06-10","lastUpdate":"2025-06-18"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tricuspid Regurgitation"],"interventions":[{"type":"DEVICE","name":"Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava","otherNames":[]}],"arms":[{"label":"Severe Tricuspid Regurgitation","type":"EXPERIMENTAL"}],"summary":"The goal of this study is to determine the short term safety (\\<30 days) and efficacy (6 months) of the heterotopic implantation of the Edwards-Sapien XT valve in the inferior vena cava for the treatment of severe tricuspid regurgitation in patients who are inoperable or at a very high surgical risk for tricuspid valve replacement.","primaryOutcome":{"measure":"Procedural Success","timeFrame":"30 days","effectByArm":[{"arm":"Severe Tricuspid Regurgitation","deltaMin":42.86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"22 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":7},"commonTop":["Gastrointestinal Bleed","Heart Failure","Shortness of Breath"]}}